Synthesis of Site Specifically-Linked Ubiquitin

US2016304571A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016304571-A1
Application numberUS-201615199392-A
CountryUS
Kind codeA1
Filing dateJun 30, 2016
Priority dateMar 24, 2010
Publication dateOct 20, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to a method of modifying a specific lysine residue in a polypeptide comprising at least two lysine residues, said method comprising (a) providing a polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue; (b) treating the polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected lysine residue of (c).

First claim

Opening claim text (preview).

1 . A method of modifying a specific lysine residue in a ubiquitin polypeptide comprising at least two lysine residues, said method comprising: (a) providing a ubiquitin polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue, wherein the ubiquitin polypeptide comprising the target lysine group is provided by genetically incorporating the target lysine residue protected by the first protecting group into the ubiquitin polypeptide chain during its translation by (i) providing a nucleic acid encoding the ubiquitin polypeptide which nucleic acid comprises an orthogonal codon encoding the target lysine; and (ii) translating said nucleic acid in the presence of an orthogonal tRNA synthetase/tRNA pair capable of recognising said orthogonal codon and incorporating said target lysine residue protected by a first protecting group into the ubiquitin polypeptide chain; (b) treating the ubiquitin polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected lysine residue of (c). 2 . A method according to claim 1 wherein said orthogonal codon comprises TAG, said tRNA comprises MbtRNA CUA and said tRNA synthetase comprises MbPylRS. 3 . A method according to claim 1 , wherein the target lysine residue protected by a first protecting group is Nε-(t-butyloxycarbonyl)-L-lysine. 4 . A method according to claim 1 , wherein the protecting group for said further lysine residues is N-(benzyloxycarbonyloxy) succinimide (Cbz-Osu). 5 . A method according to claim 1 wherein step (b) comprises treating the polypeptide with N-(benzyloxycarbonyloxy) succinimide (Cbz-OSu) in basic DMSO. 6 . A method according to claim 1 wherein step (c) comprises treating the polypeptide with trifluoroacetic (TFA) acid in water. 7 . A method according to claim 1 wherein the modification of step (d) is carried out on the ε-amino group of the target lysine residue. 8 . A method according to claim 1 wherein multiple modifications are made to the target lysine in step (d). 9 . A method according to claim 1 further comprising the step (e) deprotecting said further lysine residue(s). 10 . A method according to claim 1 , wherein the modification of step (d) is the covalent linkage of a further polypeptide chain to the target lysine. 11 . A method according to claim 10 wherein the further polypeptide chain is ubiquitin. 12 . The method according to claim 1 , wherein steps (c)-(d) are repeated to produce a chain of polypeptides joined by covalent linkages through lysine residues. 13 . A method of modifying a specific lysine residue in a ubiquitin polypeptide comprising at least two lysine residues, said method comprising: (a) providing a ubiquitin polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue, wherein the ubiquitin polypeptide comprising the target lysine group is provided by genetically incorporating the target lysine residue protected by the first protecting group into the ubiquitin polypeptide chain during its translation by (i) providing a nucleic acid encoding the ubiquitin polypeptide which nucleic acid comprises an orthogonal codon encoding the target lysine; and (ii) translating said nucleic acid in the presence of an orthogonal tRNA synthetase/tRNA pair capable of recognising said orthogonal codon and incorporating said target lysine residue protected by a first protecting group into the ubiquitin polypeptide chain; (b) treating the ubiquitin polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected target lysine by activating thioester by conversion to N-hydroxysuccinimidyl ester in the presence of Ag(I), adding a polypeptide to be joined to the target lysine; and incubating to allow formation of a specific isopeptide bond. 14 . A ubiquitin polypeptide comprising at least two lysine residues, wherein a single target lysine residue in the ubiquitin polypeptide lacks a protecting group and the remaining lysine residues in the ubiquitin polypeptide comprise a protecting group. 15 . A ubiquitin polypeptide according to claim 15 produced according to claim 1 . 16 . A ubiquitin polypeptide according to claim 15 , wherein the ubiquitin polypeptide comprises an additional polypeptide linked to the ubiquitin polypeptide through the target lysine residue. 17 . A ubiquitin polypeptide according to claim 17 , wherein the target lysine residue is K6 or K29. 18 . A ubiquitin polypeptide according to claim 15 , wherein the target lysine residue is not on a terminal end of the ubiquitin polypeptide.

Assignees

Inventors

Classifications

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • for omega-amino or -guanidino functions · CPC title

  • by covalent attachment of amino acids or peptide residues · CPC title

  • for heterocyclic side chains · CPC title

  • C12N9/64Primary

    derived from animal tissue · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016304571A1 cover?
The invention relates to a method of modifying a specific lysine residue in a polypeptide comprising at least two lysine residues, said method comprising (a) providing a polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue; (b) treating the polypeptide to protect said further lysine residue(s), wherein the protectin…
Who is the assignee on this patent?
Medical Res Council
What technology area does this patent fall under?
Primary CPC classification C12N9/64. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Oct 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).